Association of common variations in the norepinephrine transporter gene with response to olanzapine-fluoxetine combination versus continued-fluoxetine treatment in patients with treatment-resistant depression: A candidate gene analysis

Journal of Clinical Psychiatry

Volumn 73, Issue 6, 2012, Pages 878-885

  Houston, John P ^a   Lau, Kit ^c   Aris, Virginie ^c   Liu, Wenlei ^b   Fijal, Bonnie A ^b   Heinloth, Alexandra N ^c   Perlis, Roy H ^d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c SYNEOS HEALTH   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DOPAMINE; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; MELANOCORTIN 3 RECEPTOR; NORADRENALIN; NORADRENALIN TRANSPORTER; OLANZAPINE; TRYPTOPHAN HYDROXYLASE 2;

ADULT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; FEMALE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENE MAPPING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOCORTIN 3 RECEPTOR GENE; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NOREPINEPHRINE TRANSPORTER GENE; POST HOC ANALYSIS; PREDICTIVE VALUE; PREFRONTAL CORTEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; TRYPTOPHAN HYDROXYLASE 2 GENE;

EID: 84863547954     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10m06744     Document Type: Article

References (49)

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51(1):8-19. PubMed (Pubitemid 24028993)
2. Waraich P, Goldner EM, Somers JM, et al. Prevalence and incidence studies of mood disorders: a systematic review of the literature. Can J Psychiatry. 2004;49(2):124-138. PubMed (Pubitemid 38387422)
3. Rush AJ, Trivedi MH, Wisniewski SR, et al; STAR*D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231-1242. doi:10.1056/NEJMoa052963 PubMed
4. Symbyax [package insert]. Indianapolis, IN: Eli Lilly and Company; 2010.
5. Perlis RH, Moorjani P, Fagerness J, et al. Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study. Neuropsychopharmacology. 2008;33(12):2810-2819. doi:10.1038/np.208.6 PubMed
6. Binder EB, Owens MJ, Liu W, et al. Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. Arch Gen Psychiatry. 2010;67(4):369-379. doi:10.101/archgenpsychiatry.2010.18 PubMed
7. Uher R, Perroud N, Ng MY, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry. 2010;167(5):555-564. doi:10.176/api.ajp.209.09070932 PubMed
8. Baune BT, Dannlowski U, Domschke K, et al. The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression. Biol Psychiatry. 2010;67(6):543-549. doi:10.1016/j.biopsych.209.1.04 PubMed
9. Tzvetkov MV, Brockmöller J, Roots I, et al. Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment. Pharmacogenet Genomics. 2008;18(6):495-506. doi:10.1097/FPC.0b013e3282fb02cb PubMed (Pubitemid 351769917)
10. Zou YF, Ye DQ, Feng XL, et al. Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. Eur Neuropsychopharmacol. 2010;20(8):535-544. doi:10.1016/j.euroneuro.209.12.05 PubMed
11. Perlis RH, Fijal B, Adams DH, et al. Variation in catechol- Omethyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biol Psychiatry. 2009;65(9):785-791. doi:10.1016/j.biopsych.208.10.02 PubMed
12. Yoshida K, Takahashi H, Higuchi H, et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry. 2004;161(9):1575-1580. doi:10.176/api.ajp.161.9.1575 PubMed (Pubitemid 39201453)
13. Mrazek DA, Rush AJ, Biernacka JM, et al. SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet. 2009;150B(3):341-351. doi:10.102/ajmg.b.30816 PubMed
14. McMahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006;78(5):804-814. doi:10.1086/503820 PubMed
15. Horstmann S, Lucae S, Menke A, et al. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology. 2010;35(3):727-740. doi:10.1038/np.209.180 PubMed
16. Garriock HA, Tanowitz M, Kraft JB, et al. Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. Am J Psychiatry. 2010;167(5):565-573. doi:10.176/api.ajp.209.0808167 PubMed
17. Papiol S, Arias B, Gastó C, et al. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J Affect Disord. 2007;104(1-3):83-90. doi:10.1016/j.jad.207.02.017 PubMed (Pubitemid 350052308)
18. Wong ML, Whelan F, Deloukas P, et al. Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proc Natl Acad Sci U S A. 2006;103(41):15124-15129. doi:10.1073/pnas.0602795103 PubMed (Pubitemid 44583175)
19. Malhotra AK. The pharmacogenetics of depression: enter the GWAS. Am J Psychiatry. 2010;167(5):493-495. doi:10.176/api.ajp.2010.102024 PubMed
20. Lekman M, Laje G, Charney D, et al. The FKBP5-gene in depression and treatment response-an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol Psychiatry. 2008;63(12):1103-1110. doi:10.1016/j.biopsych.207.10.026 PubMed
21. Lewis CM, Ng MY, Butler AW, et al. Genome-wide association study of major recurrent depression in the UK population. Am J Psychiatry. 2010;167(8):949-957. doi:10.176/api.ajp.2010.09091380 PubMed
22. Ising M, Lucae S, Binder EB, et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry. 2009;66(9):966-975. doi:10.101/ archgenpsychiatry.209.95 PubMed
23. Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry. 2007;68(2):224-236. doi:10.408/JCP.v68n0207 PubMed (Pubitemid 46362643)
24. Zhang W, Perry KW, Wong DT, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology. 2000;23(3):250-262. doi:10.1016/S0893-13X(0)019-6 PubMed
25. Montgomery SA, Smeyatsky N, de Ruiter M, et al. Profiles of antidepressant activity with the Montgomery-Asberg Depression Rating Scale. Acta Psychiatr Scand suppl. 1985;72(s320):38-42. doi:10.1/j.160-047.1985.tb08073.x PubMed (Pubitemid 16219439)
26. Zou YF, Wang Y, Liu P, et al. Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients. Neuropsychobiology. 2010;61(2):71-78. doi:10.159/0265132 PubMed
27. Viikki M, Kampman O, Illi A, et al. TPH1 218A/C polymorphism is associated with major depressive disorder and its treatment response. Neurosci Lett. 2010;468(1):80-84. doi:10.1016/j.neulet.209.10.069 PubMed
28. Kishi T, Yoshimura R, Kitajima T, et al. HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort. Neuromolecular Med. 2010;12(3):237-242. doi:10.107/s12017-09-8105-y PubMed
29. Kishi T, Kitajima T, Tsunoka T, et al. Genetic association analysis of serotonin 2A receptor gene (HTR2A) with bipolar disorder and major depressive disorder in the Japanese population. Neurosci Res. 2009;64(2):231-234. doi:10.1016/j.neures.209.03.03 PubMed
30. Harvey M, Gagné B, Labbé M, et al. Polymorphisms in the neuronal isoform of tryptophan hydroxylase 2 are associated with bipolar disorder in French Canadian pedigrees. Psychiatr Genet. 2007;17(1):17-22. PubMed doi:10.1097/YPG.0b013e3280187
31. Zhang YQ, Yuan GZ, Li GL, et al. [A case-control study on the risk factors for attempted suicide in patients with major depression]. Zhonghua Liu Xing Bing Xue Za Zhi. 2007;28(2):131-135. PubMed
32. Adams DH, Close S, Farmen M, et al. Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder. Hum Psychopharmacol. 2008;23(4):267-274. doi:10.102/hup.930 PubMed (Pubitemid 351982663)
33. Houston JP, Adams DH, Kirkwood SC, et al. Neuroreceptor gene polymorphisms and olanzapine depressive symptom response in schizophrenia. J Clin Psychopharmacol. 2007;27(5):520-523. doi:10.1097/JCP.0b013e31814f4d82 PubMed (Pubitemid 47415058)
34. Reynolds GP, Arranz B, Templeman LA, et al. Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am J Psychiatry. 2006;163(10):1826-1829. doi:10.176/api.ajp.163.10.1826 PubMed (Pubitemid 44522494)
35. Ellingrod VL, Lund BC, Miller D, et al. 5-HT2A receptor promoter polymorphism, -1438G/A and negative symptom response to olanzapine in schizophrenia. Psychopharmacol Bull. 2003;37(2):109-112. PubMed
36. Yu YW, Tsai SJ, Lin CH, et al. Serotonin-6 receptor variant (C267T) and clinical response to clozapine. Neuroreport. 1999;10(6):1231-1233. doi:10.1097/01756-1904260-014 PubMed (Pubitemid 29403700)
37. Dlugos AM, Hamidovic A, Palmer AA, et al. Further evidence of association between amphetamine response and SLC6A2 gene variants. Psychopharmacology (Berl). 2009;206(3):501-511. doi:10.107/s0213-09-1628-y PubMed
38. Burnham KP, Andersen DR. Multimodal inference: Understanding AIC and BIC in Model Selection. Sociol Methods Res. 2004;33(2):261-304. doi:10.17/ 04912410426864 (Pubitemid 39519124)
39. Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity. 2005;95(3):221-227. doi:10.1038/sj.hdy.680717 PubMed (Pubitemid 43093236)
40. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet. 2004;74(4):765-769. doi:10.1086/383251 PubMed (Pubitemid 38420107)
41. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc Ser B. 1995;57(1):289-300.
42. Uher R, Huezo-Diaz P, Perroud N, et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J. 2009;9(4):225-233. doi:10.1038/tpj.209.12 PubMed
43. Haenisch B, Linsel K, Brüss M, et al. Association of major depression with rare functional variants in norepinephrine transporter and serotonin1A receptor genes. Am J Med Genet B Neuropsychiatr Genet. 2009;150B(7):1013-1016. doi:10.102/ajmg.b.30912 PubMed
44. Ramoz N, Boni C, Downing AM, et al. A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD). Neuropsychopharmacology. 2009;34(9):2135-2142. doi:10.1038/np.209.39 PubMed
45. Tsai SJ, Hong CJ, Liou YJ, et al. Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(4):637-641. doi:10.1016/j.pnpbp. 209.02.020 PubMed
46. Lim JE, Pinsonneault J, Sadee W, et al. Tryptophan hydroxylase 2 (TPH2) haplotypes predict levels of TPH2 mRNA expression in human pons. Mol Psychiatry. 2007;12(5):491-501. PubMed (Pubitemid 46652452)
47. Obregón AM, Amador P, Valladares M, et al. Melanocortin-3 receptor gene variants: association with childhood obesity and eating behavior in Chilean families. Nutrition. 2010;26(7-8):760-765. doi:10.1016/j.nut.209.07.05 PubMed
48. Lee YS, Poh LK, Kek BL, et al. The role of melanocortin 3 receptor gene in childhood obesity. Diabetes. 2007;56(10):2622-2630. doi:10.237/db07-025 PubMed (Pubitemid 47523271)
49. Perlis RH, Adams DH, Fijal B, et al. Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression. J Clin Psychiatry. 2010;71(5):599-605.